J. Lipid Res. Neurobiology of Lipids (ISSN1683-5506)
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1194/jlr.M300486-JLR200 on February 16, 2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
M300486-JLR200v1
45/5/933    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, Y.-Y.
Right arrow Articles by Cabot, M. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, Y.-Y.
Right arrow Articles by Cabot, M. C.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of Lipid Research, Vol. 45, 933-940, May 2004
Copyright © 2004 by American Society for Biochemistry and Molecular Biology

Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells

Yong-Yu Liu1,*, Tie Yan Han*, Jing Yuan Yu*, Arie Bitterman{dagger}, Ahn Le*, Armando E. Giuliano* and Myles C. Cabot1,*

* John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA
{dagger} Department of Surgery A, Carmel Medical Center, Haifa, Israel

1 To whom correspondence should be addressed. e-mail: yong{at}jwci.org (Y-Y.L.); cabot{at}jwci.org (M.C.C.)

High glucosylceramide synthase (GCS) activity is one factor contributing to multidrug resistance (MDR) in breast cancer. Enforced GCS overexpression has been shown to disrupt ceramide-induced apoptosis and to confer resistance to doxorubicin. To examine whether GCS is a target for cancer therapy, we have designed and tested the effects of antisense oligodeoxyribonucleotides (ODNs) to GCS on gene expression and chemosensitivity in multidrug-resistant cancer cells. Here, we demonstrate that antisense GCS (asGCS) ODN-7 blocked cellular GCS expression and selectively increased the cytotoxicity of anticancer agents. Pretreatment with asGCS ODN-7 increased doxorubicin sensitivity by 17-fold in MCF-7-AdrR (doxorubicin-resistant) breast cancer cells and by 10-fold in A2780-AD (doxorubicin-resistant) ovarian cancer cells. In MCF-7 drug-sensitive breast cancer cells, asGCS ODN-7 only increased doxorubicin sensitivity by 3-fold, and it did not influence doxorubicin cytotoxicity in normal human mammary epithelial cells. asGCS ODN-7 was shown to be more efficient in reversing drug resistance than either the GCS chemical inhibitor D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol or the P-glycoprotein blocking agents verapamil and cyclosporin A. Experiments defining drug transport and lipid metabolism parameters showed that asGCS ODN-7 overcomes drug resistance mainly by enhancing drug uptake and ceramide-induced apoptosis.

This study demonstrates that a 20-mer asGCS oligonucleotide effectively reverses MDR in human cancer cells.

Abbreviations: asGCS, antisense glucosylceramide synthase; GCS, glucosylceramide synthase (ceramide:UDP-glucosyltransferase); HMEC, human mammary epithelial cells; NB-DNJ, N-butyldeoxynojirimycin; OD, optical density; ODN, oligodeoxyribonucleotide; PDMP, D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol

Supplementary key words ceramide • antisense oligonucleotides • apoptosis • chemotherapy • breast cancer • doxorubicin • drug uptake • D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-propanol


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 FASEB J.Home page
Y.-Y. Liu, J. Y. Yu, D. Yin, G. A. Patwardhan, V. Gupta, Y. Hirabayashi, W. M. Holleran, A. E. Giuliano, S. M. Jazwinski, V. Gouaze-Andersson, et al.
A role for ceramide in driving cancer cell resistance to doxorubicin
FASEB J, July 1, 2008; 22(7): 2541 - 2551.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. Jones, H. Otu, D. Spentzos, S. Kolia, M. Inan, W. D. Beecken, C. Fellbaum, X. Gu, M. Joseph, A. J. Pantuck, et al.
Gene Signatures of Progression and Metastasis in Renal Cell Cancer
Clin. Cancer Res., August 15, 2005; 11(16): 5730 - 5739.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Journal of Biological Chemistry 
 Molecular and Cellular Proteomics   ASBMB Today 
Copyright © 2004 by the American Society for Biochemistry and Molecular Biology.